Biological
MRNA-1283 clinical trials
Also written mRNA-1283.
- studies test it
- 5
- open now
- 2
- in phase 3
- 0
- first study started
- 2021
Keep track of what changes. Save the MRNA-1283 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2021 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses MRNA-1283 is read from its arms, and is right about nine times in ten.
Testing it · 5
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingPhase 4ModernaTX, Inc.NCT07863635Written as mRNA-1283
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingPhase 2ModernaTX, Inc.NCT07808697Written as mRNA-1283
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingPhase 4ModernaTX, Inc.NCT07266558Written as mRNA-1283
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedPhase 2ModernaTX, Inc.NCT05137236Written as mRNA-1283
- A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19CompletedPhase 1ModernaTX, Inc.NCT04813796Written as mRNA-1283